CN106798734A - A kind of soft capsule containing Co-Q10 and its preparation and application - Google Patents
A kind of soft capsule containing Co-Q10 and its preparation and application Download PDFInfo
- Publication number
- CN106798734A CN106798734A CN201510830305.XA CN201510830305A CN106798734A CN 106798734 A CN106798734 A CN 106798734A CN 201510830305 A CN201510830305 A CN 201510830305A CN 106798734 A CN106798734 A CN 106798734A
- Authority
- CN
- China
- Prior art keywords
- ubiquinone
- weight portions
- capsule
- beeswax
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007901 soft capsule Substances 0.000 title claims abstract description 73
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 87
- 239000002285 corn oil Substances 0.000 claims abstract description 54
- 235000005687 corn oil Nutrition 0.000 claims abstract description 54
- 235000013871 bee wax Nutrition 0.000 claims abstract description 47
- 239000012166 beeswax Substances 0.000 claims abstract description 46
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 43
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 43
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 43
- 229940046009 vitamin E Drugs 0.000 claims abstract description 43
- 239000011709 vitamin E Substances 0.000 claims abstract description 43
- 230000000694 effects Effects 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 30
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 29
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 29
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229940035936 ubiquinone Drugs 0.000 claims abstract description 26
- 239000002994 raw material Substances 0.000 claims description 31
- 230000019612 pigmentation Effects 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000002775 capsule Substances 0.000 claims description 17
- 108010010803 Gelatin Proteins 0.000 claims description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- 239000008273 gelatin Substances 0.000 claims description 16
- 229920000159 gelatin Polymers 0.000 claims description 16
- 235000019322 gelatine Nutrition 0.000 claims description 16
- 235000011852 gelatine desserts Nutrition 0.000 claims description 16
- 230000036039 immunity Effects 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 16
- 239000003292 glue Substances 0.000 claims description 13
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 8
- 239000008213 purified water Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 241000228347 Monascus <ascomycete fungus> Species 0.000 claims description 4
- 238000004040 coloring Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000004408 titanium dioxide Substances 0.000 claims description 4
- 230000001815 facial effect Effects 0.000 claims description 3
- 238000004513 sizing Methods 0.000 claims description 3
- 235000010215 titanium dioxide Nutrition 0.000 claims description 3
- 239000002904 solvent Substances 0.000 abstract description 9
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 238000004090 dissolution Methods 0.000 abstract description 2
- 230000003712 anti-aging effect Effects 0.000 abstract 1
- 238000005453 pelletization Methods 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 57
- 239000000047 product Substances 0.000 description 33
- 239000000463 material Substances 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 16
- 230000000242 pagocytic effect Effects 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 230000006870 function Effects 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 13
- 210000003743 erythrocyte Anatomy 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 241000287828 Gallus gallus Species 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 206010016256 fatigue Diseases 0.000 description 11
- 210000002540 macrophage Anatomy 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 210000004698 lymphocyte Anatomy 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 9
- 239000005515 coenzyme Substances 0.000 description 9
- 230000036737 immune function Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 108010006464 Hemolysin Proteins Proteins 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 239000003228 hemolysin Substances 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 210000002683 foot Anatomy 0.000 description 7
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 230000007815 allergy Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 210000000822 natural killer cell Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000001541 thymus gland Anatomy 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 210000003024 peritoneal macrophage Anatomy 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 230000007306 turnover Effects 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000000976 ink Substances 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N para-benzoquinone Natural products O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 3
- 125000004151 quinonyl group Chemical group 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- BUCXEFZXWKUCCY-UHFFFAOYSA-N 4-methyl-3-(2-phenylethyl)-1,2,4-oxadiazol-5-one Chemical compound O1C(=O)N(C)C(CCC=2C=CC=CC=2)=N1 BUCXEFZXWKUCCY-UHFFFAOYSA-N 0.000 description 2
- 241000256844 Apis mellifera Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 208000019914 Mental Fatigue Diseases 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 241000863032 Trieres Species 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000011207 functional examination Methods 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 208000033065 inborn errors of immunity Diseases 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000009973 maize Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- -1 oxygen radical Ion Chemical class 0.000 description 2
- 238000002229 photoelectron microspectroscopy Methods 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000009967 tasteless effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YHQXBTXEYZIYOV-UHFFFAOYSA-N 3-methylbut-1-ene Chemical group CC(C)C=C YHQXBTXEYZIYOV-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical class OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical class [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000010461 other edible oil Substances 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- SOECUQMRSRVZQQ-UHFFFAOYSA-N ubiquinone-1 Chemical compound COC1=C(OC)C(=O)C(CC=C(C)C)=C(C)C1=O SOECUQMRSRVZQQ-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of ubiquinone for alleviating physical fatigue, anti-aging10Soft capsule and its preparation method and application.The ubiquinone10Capsule-core composition and the weight portion composition of soft capsule are as follows：Ubiquinone1020 50 weight portions, the weight portion of vitamin E 15 60, the weight portion of corn oil 200 500, the weight portion present invention application ubiquinone of beeswax 5 2010Physiological function effect, be aided with vitamin E, and screen the solvent with synergy, compacting pelletization, improves the stability of product, and the dissolution rate of finished product is good, be conducive to absorption of human body, the effect with good fatigue-relieving, anti-aging has preferable application prospect.
Description
Technical field
The present invention relates to a kind of soft capsule health product and its preparation method and application, and in particular to Yi Zhonghan
There is ubiquinone10Soft capsule and its preparation and application, belong to health product technical field.
Background technology
Immune refers to that body immune system recognizes itself and dissident's material, and is excluded by immune response anti-
Originality foreign matter, with the function of maintaining organism physiology to balance.The immunity of human body has and is divided into congenital immunity
With acquired immunity, both acquisition pattern differences.When a variety of reasons cause the immune of body
System is lacked of proper care, and the protective effect of immune system is affected, so as to result in the generation of disease.Exempt from
What epidemic disease power lowly often showed is exactly liable to illness, One's spirits are drooping, easy fatigue, appetite reduction etc.
Symptom.
Fatigue is a kind of physiological phenomenon, is a kind of protective mechanism for people.This is body to me
Send the signal that rest, if no matter ignored, body will suffer damage, and finally be overworked for a very long period into
Disease.Fatigue generally can be divided into physical fatigue, mental fatigue, mental fatigue and pathology fatigue.Fatigue can
Cause big energy to be consumed, kinotoxin is produced in vivo.Kinotoxin stimulates nervous centralis, produces
Whole body fatigue is reacted.Because energy is not enough, cell viability declines, and each systemic-function of body goes down,
Kinotoxin is built up in vivo, and vivo environment deteriorates, cytotoxic, excitement decay.These factors,
It is highly susceptible to induce passive death.
Research finds that, when the hypoimmunity of body, internal free radical, simple gland peptide oxygen will be produced
Raw peroxidation.
Ubiquinone in human body10Total content be only 500-1500mg and reduced with older.People's
Ubiquinone in organ10Content peaked at 20 years old, it is then rapid to reduce.The coenzyme in heart
Q10The reduction of concentration is particularly evident.Ubiquinone in the young Autopsy Cases of the old man than 20 years old of 77 years old10
Reduce 57%.
Ubiquinone10Important physiological function is played in human body as a kind of coenzyme of vitamins.It
Participate in the generation process of Mitochondria and ATP, regulating cell redox environment.It is auxiliary
Enzyme Q10With metabolic cardiac stimulant function, there is strong effect of scavenging radical, the antioxidase in human body
In the presence of, suppress damage of the free radical to biomembrane, it is natural antioxidant and radicals scavenging
Agent.Ubiquinone10It is the pith of immune link.When internal ubiquinone10Level raise when, exempt from
Epidemic disease system can more be helped from the use of antibiotic and antiviral drugs.But antibiotic
Can not help the reconstruction of immune system, and ubiquinone10Can stimulating immune system naturally so that
To larger range of benefit and resisting effect.Meanwhile, ubiquinone10Or vitamin E synergist.It is auxiliary
Enzyme Q10The work of LDL oxidation is being prevented with redder than vitamin E, carrotene and tomato
Element is stronger.It is different in vivo although the main matter for preventing lipid oxidation in vivo is vitamin E
Under conditions of, vitamin E can accelerate the oxidation of lipid in turn.This phenomenon can be prevented is exactly auxiliary
Enzyme Q10.Ubiquinone10Make vitamin E vigor palingenesis with vitamin c class seemingly, be unique one
Plant naturally occurring, the fat-soluble antioxidant that can be regenerated (change into activity form) in human body.Mesh
Before, in the market ubiquinone10It is widely used to Medicines and Health Product and cosmetics.
Ubiquinone at room temperature10It is yellow to orange-yellow crystalline powder, fusing point is relatively low (49-52 DEG C), nothing
It is smelly tasteless, it is atomic to be dissolved in ethanol in the organic solvent such as dissolvable chloroform, ether or petroleum ether,
Water insoluble and methyl alcohol.Ubiquinone10Bioavilability it is very poor, be unsuitable for absorption of human body；Ubiquinone10
To light sensitive, meet light and resolve into red material, temperature and humidity influences smaller to it.
Soft capsule mean by a certain amount of medicine, medicinal substances extract add suitable auxiliary material be sealed in it is spherical,
The formulation being made in the soft capsule material of oval or other shapes.
The content of the invention
The purpose of the present invention is exactly the health care needs for meeting current sub-health population, and is tackled above-mentioned existing
The technical problem of presence provides a kind of strengthen immunity, the ubiquinone of fatigue-relieving function10Soft capsule and its
Preparation method.
The purpose of the present invention can be achieved through the following technical solutions:
A kind of ubiquinone10Soft capsule, including utricule and the capsule-core enclosed in utricule, described capsule-core by with
The raw material composition of lower component and weight portion：Ubiquinone1020-50 weight portions, vitamin E 15-60 weight portions,
Corn oil 200-500 weight portions, beeswax 5-20 weight portions.
Further, described capsule-core is made up of the raw material of following components and weight portion：Ubiquinone1030-40 weights
Amount part, vitamin E 25-55 weight portions, corn oil 300-450 weight portions, beeswax 5.5-18 weight portions.
Further, described capsule-core is made up of the raw material of following components and weight portion：Ubiquinone1035-40
Weight portion, vitamin E 45-50 weight portions, corn oil 380-400 weight portions, beeswax 10-15 weight portions.
Further, described capsule-core is made up of the raw material of following components and weight portion：Ubiquinone1040 weights
Amount part, the weight portion of vitamin E 50, the weight portion of corn oil 395, the weight portion of beeswax 15.
Ubiquinone of the present invention10Soft capsule is prepared as follows：
(1) preparation of capsule-core feed liquid：Beeswax, corn oil, heating fusing beeswax are taken by formula rate；By matching somebody with somebody
Square ratio takes vitamin E, ubiquinone10, mix with beeswax, corn oil, obtain capsule-core feed liquid；
(2) preparation of capsule hide glue gelatin：Purified water is heated, by gelatin, glycerine, titanium dioxide, burnt sugar coloring,
Monascus color is added in purified water, heating, and stirring obtains capsule hide glue gelatin；
(3) soft capsule is prepared：The capsule hide glue gelatin that capsule-core feed liquid obtained in step (1) and step (2) are prepared
Mix, by pelleting, sizing, dry, prepare coenzyme Q 10 soft capsule.
Further, the weight portion of gelatin, glycerine and pure water used in step (2) is 1~5:0.5~2:2~8.
Further, the weight portion of selected gelatin, glycerine and pure water is 3:1:4.
The present invention provides a kind of composition and is preparing the health care with strengthen immunity, fatigue-relieving effect
Application in product, the raw material of the composition is by as follows into being grouped into：
Ubiquinone1020-50 weight portions, vitamin E 15-60 weight portions, corn oil 200-500 weight portions,
Beeswax 5-20 weight portions.
Further, it is made up of the raw material of following components and weight portion：Ubiquinone1030-40 weight portions, dimension life
Plain E 25-55 weight portions, corn oil 300-450 weight portions, beeswax 5.5-18 weight portions.
Further, it is made up of the raw material of following components and weight portion：Ubiquinone1035-40 weight portions, dimension
Raw element E 45-50 weight portions, corn oil 380-400 weight portions, beeswax 10-15 weight portions.
Further, it is made up of the raw material of following components and weight portion：Ubiquinone1040 weight portions, dimension life
The weight portions of plain E 50, the weight portion of corn oil 395, the weight portion of beeswax 15.
The present invention provides a kind of composition in preparing with the health products for dispelling facial pigmentation effect
Application, the raw material of the composition is by as follows into being grouped into：
Ubiquinone1020-50 weight portions, vitamin E 15-60 weight portions, corn oil 200-500 weight portions,
Beeswax 5-20 weight portions.
Further, it is made up of the raw material of following components and weight portion：Ubiquinone1030-40 weight portions, dimension life
Plain E 25-55 weight portions, corn oil 300-450 weight portions, beeswax 5.5-18 weight portions.
Further, it is made up of the raw material of following components and weight portion：Ubiquinone1035-40 weight portions, dimension
Raw element E 45-50 weight portions, corn oil 380-400 weight portions, beeswax 10-15 weight portions.
Further, it is made up of the raw material of following components and weight portion：Ubiquinone1040 weight portions, dimension life
The weight portions of plain E 50, the weight portion of corn oil 395, the weight portion of beeswax 15.
Primary raw material ubiquinone in inventive formulation10(Coenzyme Q10) also known as Ubidecarenone, are a kind of
Quinone cyclics, its structure is similar to vitamin K, the ubiquinone side chain iso-amylene unit of separate sources
Number it is different, in the ubiquinone of the mankind and other mammals, isopentene group unit numbers are for 10
Gain the name, have presence in the heart, liver, kidney, the pancreas in human body, the function of determination is compared at present there are two
Aspect, one is played an important role during nutriment is converted into energy in mitochondria, is thin
The activator that born of the same parents breathe and are metabolized；Two is have obvious lipoid peroxidization resistant, is important anti-oxidant
Agent；In recent years, scholar observes, ubiquinone10For the disease of malignant tumour, AIDS and ulcers
Shape has some improvement, and then proposes ubiquinone10The also effect with strengthen immunity, in machine
The non-specificity of body has the effect of Immune-enhancing effect.
Ubiquinone10Chemical name CoQ10, molecular formula
C59H90O4, molecular weight 862, structure belongs to quinone cyclics similar to vitamin K.At room temperature
In orange-yellow crystal, odorless, tasteless.Its fusing point is 49 DEG C, is influenceed smaller by temperature and humidity, but illumination
Under the conditions of it is unstable, be easily decomposed.Ubiquinone10Benzoquinones has hydroxyl substituent and makes in the quinone ring of structure
It tends to polarity, and polyisoprene side chain then makes it in hydrophobic environment with relatively low free energy,
This characteristic can spread and be enriched with rapidly in mitochondrial inner membrane.In addition, its quinone ring has typical case
Reversible oxidation reduction characteristic.Exist in quinone form under oxidative conditions, under anaerobic, can be also
Originally it was hydroquinones, the form with oxidized form, reduced form and free radical semiquinone in cell.More than being based on
Reason, ubiquinone10After receiving hydrogen from Mitochondria complex, hydrogen is on the one hand directly transmitted to free radical,
Reacted under antioxidase effect, suppress destruction of the free radical to cell membrane, on the other hand by proton
In release to mitochondrial matrix, electronics then passes to cytochromes, promotes oxidative phosphorylation and electronics actively
Transfer, is consequently formed the main matter ATP of organism ability storage, and carry by reducing AMP losses
ATP levels high, reduce calcium ion and are lost in, and maintain calcium channel integrality and stabilizing cell membrane.In reality
In the application of border, ubiquinone10It is considered as a kind of natural good antioxidant and free radical scavenger, hair
Wave the effect of the multiple efficacies such as alleviation physical fatigue, enhance immunity.Therefore ubiquinone10It is a kind of immune tune
Section agent, plays the healthcare function of strengthen immunity.Additionally, ubiquinone10Molecule is big, poorly water-soluble,
Gastrointestinal absorption is slow, and the time that valid density is reached after oral administration is more long, about needs (put down within 5~10 hours
Equal 6.5 hours), therefore the present invention is from the formulation of soft capsule.
Vitamin E is a kind of liposoluble vitamin being widely present in natural animal-plant, also known as tocopherol,
To sour and thermally-stabilised, in the presence of having oxygen, it is heated to 200 DEG C and remains to keep stabilization.Vitamin E has
There are different physiological roles, be also that one of vitamin needed by human is one of topmost antioxidant.Dimension life
Plain E is positioned on cell membrane, belongs to fat-soluble chain rupture type antioxidant, and it provides hydrogen to fat oxygen radical
Ion, makes lipid peroxidation chain interruption, the structure together with superoxide dismutase, glutathione peroxidase
Antioxidant system in adult, protects cell membrane and intracellular nucleic acid from the attack of free radical.Additionally,
Vitamin E can also melt go out singlet oxygen, improve the oxidation resistance of solvent naphtha.In formula of the invention,
Addition vitamin E can effectively protect ubiquinone as auxiliary material10Oxidative inactivation.
Vitamin E is formed by Hydrolysis kinetics in natural plants, compared to synthesising complex E security more
Height, vitamin E absorbs high 3.5 times than composite, and half-life period is longer, and physiologically active is approximately composite
3-8 times.Thus the present invention selects vitamin E as the major auxiliary burden of addition.
Ubiquinone10Belong to liposoluble substance, according to the similar principle for mixing, select oily substance as flexible glue
Capsule matrix.Corn oil be it is a kind of by maize extract high quality food oil, and its natural anti-oxidation and
Stability is fairly good, high temperature resistant frying.Corn oil is rich in unrighted acid, and its Linoleic acid accounts for grease
More than the 50% of total amount, rich in vitamin E, phytosterol, phosphatide etc., is in the world referred to as corn oil
Nutrition oil, is usually used in medicine and health food production.Linoleic acid contained by corn oil is human body
Essential fatty acid, it is not only the necessary constituent of cell membrane, is also the base of body synthesis of prostaglandins
Plinth material, it can be combined into ester, promote the transhipment of cholesterol, and promote cholesterol to be changed into cholesterol
Cholic acid is excreted, and has good effect for reducing fat, moreover it is possible to is suppressed blood platelet aggegation on vascular wall, is prevented
Thrombosis, plays antiatherosclerosis, the effect of pre- angiocardiopathy.The sterol of corn oil plant
Content is that other edible oils can not compare, and sterol has the work for directly, effectively, quickly reducing cholesterol
With.Modern medicine field of food has developed corn oil for the preventing and treating of cardiovascular and cerebrovascular disease.Meanwhile, it is modern
Research is tested mouse, and researcher has found long-term maize of the intake rich in polyunsaturated fatty acid
Bud oil, may change the species and level of aliphatic acid in mouse immune cell membrane phospholipid, so as to improve
The immunity of mouse, points out the effect with enhancing mouse immunity.The present invention is flexible glue from corn oil
The matrix of capsule, can both solve ubiquinone10Indissoluble sex chromosome mosaicism, the Multiple components that wherein corn oil contains
With auxiliary lipid-lowering function, corn oil is big compared to the proportioning consumption that other are invented in invention, and it sets out
It is corn oil consumption and security reliability in itself to select, and corn oil has good health-care efficacy in itself,
Therefore the present invention improves the proportioning consumption of corn oil, it is intended to strengthen ubiquinone10Anti-oxidant and regulation reducing blood lipid
Function, the two is mutually applied more is beneficial to immunizing health effect of product.Found in experimentation
It is simple to utilize corn oil to ubiquinone10Dissolved not thorough, easily before the encapsulated of soft capsule, encapsulated
During and encapsulated after corn oil in produce solids sedimentation, and production and old storage during
Sedimentation can slowly be layered, be helped to ensure that suspending liquid has good stability, therefore need to add wherein
Suspension, suspending agent can be played to be prevented from settling, is layered, it is ensured that the suspending of product, it is ensured that the standard of loading amount
Really.Conventional oiliness suspending agent has ceride class, lecithin, aluminum monostearate etc. at present, it is contemplated that raw material
It is economic, practical with it is safe, it is most suitable using beeswax.Beeswax is the wax of honeybee secretion, and honeycomb is through excluding
Or obtained a kind of organic mixture after centrifugation removal honey, beeswax can be by influenceing system viscosity and rheology
Property is learned, every stability indicator is changed.Concentration of beeswax is higher, and plastic yield is bigger, starts
The time for settling gets over extension, and sinking speed is smaller, meets stokes formula.Further, since beeswax
Main component be palmitic acid beeswax alcohol ester, simultaneously containing a small amount of free polyols, thus with certain
Emulsibility, reduce surface tension, this also causes that the sinking speed of suspending liquid slows down because being obstructed.Beeswax
Safety, with low cost, the present invention uses the beeswax of certain concentration to assign product good stream as suspending agent
Dynamic property, contributes to the loading amount of soft capsule capsule-core active ingredient and the stabilization of finished dosage forms.
At present using auxiliary material and coenzyme such as dried starch, calcium monohydrogen phosphate, magnesium stearates more than domestic production technology
Q10Raw material powder is simply mixed to be dispensed again.Because Co-Q10 easily receives extraneous factor, such as light, oxidation
The influence of agent etc., causes content to decline (the maximum range of decrease is more than 20%).It is different from common hard capsule,
Formulation of the invention is soft capsule.Oral soft capsule agent and other conventional dosage forms for example tablet, hard capsule,
Granule and solution etc. are compared, with bioavilability it is high, medicine stability is good, content is accurate
The advantages of.Soft capsule is also referred to as capsule and pill, is by oils or to solution of the gelatin without dissolution, mixed
Suspension, even solid and semisolid etc. are closed in a kind of preparation in soft gel coat, are used for some property
Matter it is unstable (such as photaesthesia, it is oxidizable or volatilization, meet it is damp and hot unstable) water-insoluble or water-soluble pesticide
Thing and have the medicine of poor taste, smell, increase stability can be played, improve bioavilability and
The effect of taste masking.Many experiments at present have been compared and drawn, in solid pharmaceutical preparation oral application, soft capsule gram
The shortcomings of having taken the easy moisture absorption of hard shell capsules formulation, stability difference, while the bioavilability of preparation can be improved.
The present invention is with ubiquinone10Compounding is carried out with the specific ratio such as corn oil, vitamin E, suspending agent to be obtained,
The accelerated experiment of product and long-time stability are investigated, steady quality.Product is better than traditional solid dosage forms system
Agent, the bioavilability of product is improve with soft capsule, it is ensured that product quality as formulation.
Compared with prior art, the present invention is with ubiquinone10Be main both effectiveness composition, be aided with vitamin E,
Corn oil and beeswax are made soft capsule preparation, the healthcare function with strengthen immunity, are mainly used in enhancing
The gentle physical fatigue of immunity, anti-oxidant, auxiliary adjustment of blood fat.The product quality that the present invention is provided is steady
It is fixed, convenient to take, meet requirement of the State Food and Drug Administration to health food, safely and effectively,
Can long-term taking, be the preferable health food of hypoimmunity crowd.
Experimental example 1
Strengthen immunity function to coenzyme Q 10 soft capsule manufactured in the present embodiment is detected.
1st, sample：The soft capsule of DPN diphosphopyridine nucleotide 0 prepared by embodiment 5.
2nd, experimental animal and environment:
SPF grades of healthy Male Kunming strain mice 288, body weight 18g~22g, by Zhejiang Academy of Medical Sciences
Experimental Animal Center is provided, Quality of Experimental Animals quality certification number：NO.0051154.Every 48 mouse are I
Batch, totally 6 batches.VI VIII batches, carry out the mouse spleen lymphocyte transformation experiment of ConA inductions；II batch, carry out
Delayed allergy is tested；III batch, serum hemolysin is determined and antibody-producting cell number is determined；IV~VI
Batch, carbonic clearance experiment, peritoneal macrophage phagocytosis chicken red blood cell experiment and NK cytoactives are carried out respectively to be surveyed
It is fixed.
22 ± 2 DEG C of experimental situation temperature, relative humidity 50% ± 10%.
3rd, dose design and tested material give mode：Ubiquinone of the invention10Recommendation of the soft capsule to human body
Dosage is daily 1.0g/60kg body weight, equivalent to 0.0167g/kg, BW, by equivalent to human body recommended dose
5,10,30 multiple doses determine the low middle Three doses high of mouse, to the dosage point of mouse in the present embodiment
0.083g/kg, BW, 0.167g/kg, BW, 0.50g/kg, BW, three kind are not set to, it is oral daily
Gavage gives mouse tested material, and gavage volume presses 10ml/kg, BW.Prepared with corn oil before gavage
Tested material, in basic, normal, high dosage group the concentration of tested material be respectively 8.33g/L, 16.667g/L and
50.00g/L, negative control group replaces tested material with isometric distilled water, and solvent control group is with isometric
Corn oil replaces tested material, and every immune indexes are tested after 30 days.Mouse is with outbred mice special feed
Feeding.
4th, experimental technique
4.1 organ weight ratio values are determined
The de- white execution of cervical vertebra, takes its thymus gland, spleen after mouse weights, removes most manadesma, is blotted with filter paper dirty
Device surface blood stains are simultaneously weighed, and calculate thymus gland body weight ratio and spleen weight ratio.The data obtained PEMS
Statistical software carries out variance analysis.
The mouse lymphocyte transformation function (mtt assay) of 4.2 Con A inductions
Continuously to sample after 30 days, the de- white execution of cervical vertebra takes spleen to animal, is made splenocyte suspension, adjusts
Cell concentration is 3 × 106Individual/ml, is divided into cell suspension holes and adds 24 well culture plates China, per hole 1ml,
One hole adds 75 μ LConA liquid (equivalent to 7.Syg/ml), and 5%C02,37 DEG C of trainings are put in another hole as control
Support 68h.Culture terminates preceding 4h, per hole gentle aspiration supernatant 0.7ml, adds 0.7ml to be free of calf serum
PRMI1640 nutrient solutions, while add MTT (5mg/ml) 50 μ L/ holes, continue cultivate 4h, culture knot
Shu Hou, 1ml acid isopropyl alcohol is added per hole, and piping and druming is mixed, and after being completely dissolved purple crystal, then will
Liquid is moved into 96 orifice plates, and 3 Duplicate Samples are added per hole, and extinction is measured in 570nm wavelength with ELIASA
Angle value (A values), calculates the difference of test hole A values and control wells A values, to represent the competence for added value of lymphocyte.
Result is analyzed with variance analysis.If the multiplication capacity of tested material group lymphocyte is higher than control group, and
Difference has conspicuousness, can determine that the tested material is improved the mouse spleen lymphocyte conversion capability of ConA inductions
Effect.
4.3 delayed allergies (vola pedis thickens method) (DTH)
Sheep blood is taken, with brine 3 times, (v/v is matched somebody with somebody every mouse with physiological saline through intraperitoneal injection 2%
Put) hematocrit SRBC (2000r/min, 10min) 0.2ml, 4 days after sensitization, left and right vola pedis thickness is measured, together
One position measures 3 times, averages, and then in measuring point hypodermic injection 20%, (v/v uses physiological saline
Configuration) hematocrit SRBC20yl, 24 hours measurement left and right vola pedis thickness after injection, to attack front and rear vola pedis thickness
Difference represent the degree of DTH.The data obtained is measurement data, and variance analysis is carried out with SPSS statistical softwares,
If the difference that tested material attacks front and rear vola pedis thickness is higher than control group, and difference has conspicuousness (P<0.05),
Can conclude that the tested material is improved the effect of mouse delayed allergy ability.
4.4 antibody-producting cells determine (Jerne improves slide methods)
Continuously to sample after 30 days, after de- fiber Mianyang erythrocyte immune 5 days, animal cervical vertebra is de- to be located animal in vain
Extremely, spleen is taken out, splenocyte suspension is made, adjustment cell concentration is 5 × 106Individual/ml.Top layer is cultivated
After base (Ig agaroses add distilled water 100ml) heating for dissolving, 45 DEG C of water-bath insulations are put into, with equivalent
PH7.2-7.4, the Hanks liquid of 2 times of concentration mix, and dispense small test tube, often pipe 0.5ml, then add in pipe
50 μ L 10%SRBC, 20 μ L splenocyte suspensions are rapid to mix, and are poured into the 6cm of brush thin agar layer
On plate, after continuing to incubate 1.5h, hemolysis plaque number is counted.Result is counted with variance analysis.If
The multiplication capacity of tested material group lymphocyte is higher than control group, and difference has conspicuousness, can determine that this is tested
Thing plays the role of to strengthen mouse antibodies cell number.
4.5 mice serum hemolysin tests:
Take sheep blood, with brine 3 times, every mouse through intraperitoneal injection 2% (use normal saline,
Volume ratio) hematocrit SRBC (2000r/min, 10min) 0.2ml, after being immunized 5 days, extracts eyeball of mouse and takes blood
In centrifuge tube, place about 1 hour, solidification blood and tube wall are peeled off, serum is collected in centrifugation, uses physiology
Be respectively placed in the solidifying brassboard of micro snow different dilution factor serum to serum doubling dilution, per hole by salt solution
100 μ L, add the μ L of 0.5%SRBC suspensions 100, mix Uniform, put in wet box, in 37 DEG C of incubations 3
Hour, record hemagglutination degree, calculating antibody product (serum two-fold dilution index and aggegation degree product it
With).
Serum agglutination degree is divided into 5 grades, clicks standard determination.O grades:SRBC all sinks, and concentrates on hole
Bottom forms the round point shape of densification, and surrounding liquid clear level=SRBC major parts are deposited on bottom hole portion into round point shape,
Surrounding has the SRBC of a small amount of aggegation；11 grades:The SRBC of aggegation forms thin layer in bottom hole, and center can be with bright
It is aobvious to see a loose red point；111 grades:The SRBC of aggegation and paving be dispersed in bottom hole into a thin layer, in
The heart mays be seen indistinctly a small red dot；IV grades:Uniformly paving is dispersed in bottom hole into a thin layer to the SRBC of aggegation, coagulates
Block is sometimes into convolution shape.
The data obtained carries out variance analysis with PEMS softwares, if tested material group Hemolysin product is high
In control group, and difference has conspicuousness, can determine that tested material is improved the work of mice serum hemolysin level
With.
4.6 mouse carbonic clearance ability tests
Animal is continuously to sample after 30 days, tail vein injection 1:The india ink of 5 dilutions, treats that prepared Chinese ink injects, and stands
That is timing.2,10 minutes after injection prepared Chinese ink, the μ L of blood 20 are taken from angular vein clump respectively, and be added into 2ml
In sodium carbonate liquor, absorbance is tested at 600nm wavelength with spectrophotometer, with sodium carbonate liquor
Do blank.According to the weight of animals, liver is weighed and spleen re-computation phagocytic index, is as a result entered with variance analysis
Row statistics.If tested material group Hemolysin product is higher than control group, and difference has conspicuousness, can
Judge that tested material is improved the effect of the carbonic clearance ability of mouse monokaryon-macrophage.
4.7 Turnover of Mouse Peritoneal Macrophages swallow chicken red blood cell (half intracorporal method) experiment
Animal, per the chicken erythrocyte suspension 1ml of mouse intraperitoneal injection 20%, is spaced 30 minutes continuously to sample after 30 days,
Cervical dislocation is put to death, and is fixed on mouse plate, cuts off abdominal skin, and injecting normal saline 2ml rotates mouse plate
1 minute, abdominal cavity washing lotion lml is suctioned out, point dripped in 2 sheets, 37 DEG C of incubators are wet to incubate 30 minutes, with life
Reason saline rinse, dries, with 1:1 acetone methanol solution is fixed, 4%Giemsa- phosphate buffers dyeing 3
Minute, then dried with distilled water rinsing, oil mirror microscopy is used, calculate percentage phagocytosis and phagocytic index.Its
In, number of macrophages × 100 of the number of macrophages/counting of phagocytic rate (%)=phagocytosis chicken red blood cell；
The number of macrophages of the chicken red blood cell sum of phagocytic index=swallowed/count.
The phagocytic rate of acquired results presses X=Sin-1P1/2Converted, P is phagocytic percentage in formula, decimally
Represent, if the phagocytic rate or phagocytic index of tested material are apparently higher than control group, and difference has conspicuousness, can
Judge that tested material is improved the effect of macrophage phagocytic chicken red blood cell ability.
4.8 NK cells in mice determinations of activity:
Continuously to sample after 30 days, the de- white execution of cervical vertebra takes spleen to animal, and (effect is thin to be made splenocyte suspension
Born of the same parents), 24h YAC-1 cells plus 1640 and are cultivated completely after taking passage, and adjustment cell concentration is 4 × 105Individual/ml
(target cell), takes target cell and each 100 μ L effect targets ratio (50 of effector cell:1) culture of the hole of U-shaped 96, is added
Plate, target cell Spontaneous release hole adds target cell and each 100 μ L of nutrient solution, maximum release aperture add target cell and
Each 100 μ L of 1%NP40, above-mentioned items are equipped with three multiple holes, with 37 DEG C, 5% CO2gas incubator
Middle culture 4 hours, every hole Aspirate supernatant 100u 1 is placed in flat 96 well culture plate, while adding LDH
The μ L of matrix liquid 100, react 3min, add the HCL30 μ L of lmol/L to terminate per hole, are existed with ELIASA
A values are determined at 490mm.NK cytoactives are calculated as follows：
NK cytoactives %=(reacting hole A- Spontaneous releases hole A)/(maximum release aperture A- Spontaneous releases hole A) ×
100；
NK cytoactives need to be by X=Sin-1P1/2Data conversion is carried out, P is NK cytoactives in formula, decimally table
Show, if the phagocytic rate or phagocytic index of tested material are apparently higher than control group, and difference has conspicuousness, can sentence
Determine the effect that tested material is improved NK cells in mice activity.
5 experimental results
5.1 experimental results judge
Enhancing immunocompetence function judges：It is thin in cellular immune function, humoral immune function, monokaryon-macrophage
Born of the same parents' function, four aspect any two aspect results of NK cytoactives are positive, you can judge that the tested material has
There is strengthen immunity function.
Two experimental results wherein in cellular immune function assay project are the positive, or any experiment
Two dosage group results are the positive, can determine that cellular immune function assay result is the positive.Humoral immunity work(
Two dosage group results that two experimental results in energy measure project are positive or any experiment are sun
Property, can determine that humoral immune function measurement result is positive.In monocytes/macrophages functional examination project two
Two dosage group results that individual experimental result is positive or any experiment are positive, can determine that monokaryon _ macrophage is thin
Born of the same parents' functional examination result is positive.More than one dosage group result of NK cytoactive detections experiment is positive, can
Judge that NK cytoactives result is positive.
5.2 ubiquinones10Influence of the soft capsule to Mouse Weight is shown in Table 1
The sample of table 1 is to being immunized one group of influence of the weight of animals (gram)
Different dosage is compared with control group as can be seen from Table 1, and the weight gain of mouse is poor without conspicuousness
It is different, therefore ubiquinone10Soft capsule has not significant impact to the body weight of animal.
5.3 ubiquinones10Influence of the soft capsule to mice organs body weight ratio：It is shown in Table 2, table 3.
The ubiquinone of table 210Influence (x ± SD) of the soft capsule to mouse spleen body weight ratio
| Group | Number of animals (only) | Spleen weight ratio (mg/g) | P |
| Water control group | 10 | 5.04±0.41 | 0.773 |
| Solvent control group | 10 | 4.98±0.62 | |
| Low dose group | 10 | 4.93±0.61 | |
| Middle dose group | 10 | 4.85±0.80 | |
| High dose group | 10 | 4.69±0.68 |
The ubiquinone of table 310Influence (x ± SD) of the soft capsule to the thymus gland body weight ratio of mouse
Compared with control group, the thymus gland body weight ratio of mouse is without notable for different dosage as can be seen from Table 3
Sex differernce, therefore ubiquinone10Soft capsule has not significant impact to the thymus gland body weight ratio of animal.
5.4 ubiquinones10Influence of the soft capsule to mouse cell immunologic function
A, ubiquinone10Influence of the soft capsule to mouse delayed allergy (DTH) is shown in Table 4.
The ubiquinone of table 410Influence (x ± SD) of the soft capsule to mouse delayed allergy (DTH)
From table 4, water control group, solvent control group and 3 mouse swelling degree of the paw of dosage group
Influence is different, and influence of the middle dose group with high dose group to mouse swelling degree of the paw has obvious with control group ratio
Difference, it is believed that ubiquinone10Soft capsule is improved the ability of mouse delayed allergy (DTH).
B, ubiquinone10The influence of the mouse spleen lymphocyte transformation experiment that soft capsule is induced ConA, is shown in
Table 5.
The influence of the mouse spleen lymphocyte transformation experiment that the coenzyme Q 10 soft capsule of table 5 is induced ConA
From table 5, water control group, solvent control group and 3 dosage groups increase to the lymphocyte of mouse
Grow between ability that there was no significant difference, it is believed that ubiquinone10Soft capsule is to improving mouse lymphocyte propagation energy
Power has not significant impact.
5.4 ubiquinones10Influence of the soft capsule to mouse humoral immune function
A, ubiquinone10Influence of the soft capsule to mouse antibodies cellulation number, is shown in Table 6.
The ubiquinone of table 610Influence (x ± SD) of the soft capsule to mouse antibodies cellulation number
From table 6, water control group has obvious with the influence of middle dose group and high dose group to plaque number
Difference, it is believed that ubiquinone10Soft capsule has the ability for increasing mouse antibodies cellulation number.
B, ubiquinone10Influence of the soft capsule to mice serum hemolysin level, is shown in Table 7.
The ubiquinone of table 710Influence (x ± SD) of the soft capsule to mice serum hemolysin level
From table 7, water control group has obvious with the influence of middle dose group and high dose group antagonist product
Difference, it is believed that ubiquinone10Soft capsule has the ability for improving mice serum hemolysin level.
5.5 ubiquinones10Influence of the soft capsule to mouse monokaryon _ macrophage phagocytic function
A, ubiquinone10Influence of the soft capsule to mouse monokaryon _ macrophage carbonic clearance ability, is shown in Table 8.
The ubiquinone of table 810Influence (x ± SD) of the soft capsule to mouse monokaryon macrophage carbonic clearance ability
From table 8, water control group, solvent control group and 3 dosage groups are thin to the monokaryon-macrophage of mouse
There was no significant difference between born of the same parents' carbonic clearance ability, it is believed that ubiquinone10Soft capsule does not have to mouse carbonic clearance ability
Have a significant effect.
B, ubiquinone10Soft capsule swallows the influence of chicken red blood cell ability to Turnover of Mouse Peritoneal Macrophages, is shown in Table
9th, table 10.
The ubiquinone of table 910Influence (x ± SD) of the soft capsule to Turnover of Mouse Peritoneal Macrophages chicken red blood cell phagocytic rate
Influence (x ± SD) of the coenzyme Q 10 soft capsule of table 10 to Turnover of Mouse Peritoneal Macrophages chicken red blood cell phagocytic index
From table 9 and table 10, water control group, solvent control group and 3 dosage groups are huge to mouse peritoneal
There was no significant difference between phagocyte phagocytosis chicken red blood cell ability, it is believed that ubiquinone10Soft capsule is to mouse abdomen
Chamber macrophage phagocytic chicken red blood cell ability has not significant impact.
5.6 ubiquinones10Influence of the soft capsule to NK cells in mice activity, is shown in Table 11.
Influence (x ± SD) of the CoQ1 q soft capsules of table 11 to NK cells in mice activity
From table 11, water control group, solvent control group and 3 dosage groups are to NK cells in mice activity
Between there was no significant difference, it is believed that ubiquinone10Soft capsule has not significant impact to NK cells in mice activity.
To sum up, the ubiquinone of orally administration mouse various dose group10Soft capsule 30 days, increases to Mouse Weight
Length has no adverse effects, on mouse spleen and thymus gland body weight ratio without influence, the humoral immune function of mouse,
Cellular immune function assay result is the positive, mononuclear macrophage phagocytic activity, NK cytoactive detections
Result is feminine gender, shows ubiquinone10Soft capsule has the effect of strengthen immunity function.
Specific embodiment
Embodiment 1
A kind of ubiquinone10Soft capsule, including capsule-core and capsule skin, capsule-core is by following components and the original of weight portion
Material composition：Ubiquinone1035g, vitamin E 35g, corn oil 225g, beeswax 7.5g；
Capsule skin is made up of the raw material of following components and weight portion：Gelatin 140g, glycerine 56g, purified water
133g, titanium dioxide 0.5g, Monascus color 1.2g, burnt sugar coloring 1.0g；
Preparation method：
(1) preparation of capsule-core feed liquid：Ubiquinone10The advance mesh sieve of mistake 80 of raw material, it is standby.Honeybee is taken by formula rate
Wax, corn oil, are heated to 70 DEG C of fusing beeswaxs, stir and evenly mix, and obtain mixed material, put to room temperature, standby
With.Vitamin E, ubiquinone are taken by formula rate10, it is added in mixed material, stir and evenly mix, cross glue
Body barreling wears into the fine and smooth slurry of quality, stands vacuum outgas bubble, standby.
(2) preparation of capsule hide glue gelatin：When purified water is heated into 60 DEG C, by what is weighed up by formula rate in advance
Gelatin, glycerine, titanium dioxide, burnt sugar coloring, Monascus color are added in purified water, are sealed, and are started
Agitating paddle is stirred, and is heated to 70 DEG C, and stirring makes uniform glue, stops stirring, is stood true
Empty de-bubbled 1h, it is standby.
(3) soft capsule is prepared：By the capsule hide glue that capsule-core feed liquid obtained in step (1) is defeated and step (2) is prepared
Liquid is mixed in being transported to the storage glue groove of encapsulating machine, standby.Start encapsulating machine, by pelleting, sizing,
Wash ball, drying, pick ball and packing step, prepare ubiquinone10Soft capsule.
Embodiment 2
Difference from Example 1 is:Capsule-core is made up of the raw material of following components and weight portion:Ubiquinone10
38g, vitamin E 40g, corn oil 226g, beeswax 5.5g.
Embodiment 3
Difference from Example 1 is：Capsule-core is made up of the raw material of following components and weight portion:Coenzyme
Q1040g, vitamin E 37g, corn oil 260g, beeswax 15g.
Embodiment 4
Difference from Example 1 is：Capsule-core is made up of the raw material of following components and weight portion：Coenzyme
Q1030g, vitamin E2 5g, corn oil 286g, beeswax 5.5g.
Embodiment 5
Difference from Example 1 is：Capsule-core is made up of the raw material of following components and weight portion:Coenzyme
Q1040g, vitamin E 50g, corn oil 395g, beeswax 15g.
Embodiment 6
Difference from Example 1 is：Capsule-core is made up of the raw material of following components and weight portion:Coenzyme
Q1038g, vitamin E 27g, corn oil 200g, beeswax 5.5g.
Embodiment 7
Difference from Example 1 is：Capsule-core is made up of the raw material of following components and weight portion:Coenzyme
Q1040g, vitamin E 60g, corn oil 250g, beeswax 15g.
Embodiment 8
Difference from Example 1 is：Capsule-core is made up of the raw material of following components and weight portion:Coenzyme
Q1040g, vitamin E 37g, corn oil 200g, beeswax 10g.
Comparative examples 1
Capsule-core：Ubiquinone1048g, vitamin E 37g, corn oil 860g, beeswax 55g；
Capsule skin constituent and soft capsule preparation method are with embodiment 1.
Comparative examples 2
Capsule-core：Ubiquinone1010g, vitamin E 30g, corn oil 950g, beeswax 10g；
Capsule skin constituent and soft capsule preparation method are with embodiment 1.
Comparative examples 3
Capsule-core：Ubiquinone1040g, vitamin E 0.2g, corn oil 140g, beeswax 19.8g；
Capsule skin constituent and soft capsule preparation method are with embodiment 1.
Effect experiment：
Trier 660,30-40 Sui, 40-50 Sui (being free of 40 years old), 50-70 Sui (is free of 50
Year) each 220 people, it is divided into 11 groups, every group includes 30-40 Sui respectively, and 40-50 Sui, 50-70 Sui is each
20 people.Three groups of triers use the product of embodiment 1-8 and comparative examples 1-3 respectively.Crowd on probation
Skin is intensely dark, there is pigmentation.
Test method：Ubiquinone prepared by embodiment 1-8 and comparative examples 1-310Soft capsule is sent out at random
To trier, daily 1,60/bottle try out 2 months.
Standards of grading：
0 point：Observed under natural light, be visible by naked eyes pigmentation；
2 points：Observed under natural light, slight pigmentation, color is light brown, in 50cm or more than 50cm
Distance observation not substantially, general cosmetic or beard, chaeta can be covered；
4 points：Observed under natural light, moderate pigmentation, color yellowish-brown, in 50cm or more than 50cm
Distance observation not substantially, general cosmetic or beard, chaeta are difficult to cover；
6 points：Observed under natural light, severe pigmentation, color dark brown is observed also very outside 50cm
Substantially, general cosmetic or beard, chaeta are difficult to cover.
Therapeutic evaluation：
Therapeutic index=[scoring before (being scored after the treatment of scoring one before treatment)/treatment] * 100%
Clinical epidemic disease heals：Pigmentation all disappears, clinical symptom disappearance, and symptom score value reduces >=95%.
It is effective：Pigmentation is most of to disappear, and clinical symptoms substantially mitigate, and 95% ﹥ symptom score values subtract
Few >=70%.
Effectively：Pigmentation partial remission, clinical symptom relief, 70% ﹥ symptom scores value reduces >=30%.
It is invalid：Pigmentation disappears not substantially, and clinical symptoms do not mitigate or deteriorate, and symptom score value is reduced
﹤ 30%.
Efficient=(recovery from illness+effective+effectively)/60*100%
Trial effect is paid a return visit in questionnaire form.Trial effect such as following table：
The trial effect of the embodiment 1-8 of table 12 and comparative examples 1-3 products
| The product of embodiment 1 | 30-40 Sui/people | 40-50 Sui/people | 50-70 Sui/people | It is efficient |
| Dispel pigmentation | 16 | 16 | 16 | 80.00% |
| The product of embodiment 2 | 30-40 Sui/people | 40-50 Sui/people | 50-70 Sui/people | It is efficient |
| Dispel pigmentation | 16 | 18 | 16 | 83.30% |
| The product of embodiment 3 | 30-40 Sui/people | 40-50 Sui/people | 50-70 Sui/people | It is efficient |
| Dispel pigmentation | 16 | 16 | 17 | 81.60% |
| The product of embodiment 4 | 30-40 Sui/people | 40-50 Sui/people | 50-70 Sui/people | It is efficient |
| Dispel pigmentation | 16 | 16 | 17 | 81.60% |
| Total effective rate | 82.75% | 84.00% | 83.00% | 81.50% |
| The product of embodiment 5 | 30-40 Sui/people | 40-50 Sui/people | 50-70 Sui/people | It is efficient |
| Dispel pigmentation | 18 | 18 | 16 | 87.30% |
| The product of embodiment 6 | 30-40 Sui/people | 40-50 Sui/people | 50-70 Sui/people | It is efficient |
| Dispel pigmentation | 16 | 16 | 17 | 81.60% |
| The product of embodiment 7 | 30-40 Sui/people | 40-50 Sui/people | 50-70 Sui/people | It is efficient |
| Dispel pigmentation | 18 | 18 | 16 | 83.30% |
| The product of embodiment 8 | 30-40 Sui/people | 40-50 Sui/people | 50-70 Sui/people | It is efficient |
| Dispel pigmentation | 18 | 16 | 18 | 83.30% |
| The product of comparative examples 1 | 30-40 Sui/people | 40-50 Sui/people | 50-70 Sui/people | It is efficient |
| Dispel pigmentation | 16 | 14 | 15 | 74.20% |
| The product of comparative examples 2 | 30-40 Sui/people | 40-50 Sui/people | 50-70 Sui/people | It is efficient |
| Dispel pigmentation | 14 | 14 | 13 | 71.25% |
| The product of comparative examples 3 | 30-40 Sui/people | 40-50 Sui/people | 50-70 Sui/people | It is efficient |
| Dispel pigmentation | 15 | 15 | 14 | 76.15% |
Conclusion：From examples detailed above, soft capsule of the present invention can effectively dispel facial pigmentation, effect
Fruit is significantly better than the product of comparative examples 1-3, wherein with the effect of product obtained by the formula of embodiment 5
Fruit is optimal, efficient higher compared with other similar proportioning compositions, and therapeutic effect is more preferable.
Claims (10)
1. one kind contains ubiquinone10Soft capsule, including capsule skin and capsule-core, it is characterised in that described
Capsule-core is made up of the raw material of following components and weight portion：Ubiquinone1020-50 weight portions, vitamin E 15-60
Weight portion, corn oil 200-500 weight portions, beeswax 5-20 weight portions.
2. a kind of ubiquinone as claimed in claim 110Soft capsule, it is characterised in that described capsule-core
It is made up of the raw material of following components and weight portion：Ubiquinone1030-40 weight portions, vitamin E 25-55 weights
Amount part, corn oil 300-450 weight portions, beeswax 5.5-18 weight portions.
3. a kind of ubiquinone as claimed in claim 210Soft capsule, it is characterised in that described capsule-core
It is made up of the raw material of following components and weight portion：Ubiquinone1035-40 weight portions, vitamin E 45-50 weights
Amount part, corn oil 380-400 weight portions, beeswax 10-15 weight portions.
4. a kind of ubiquinone as claimed in claim 310Soft capsule, it is characterised in that described capsule-core
It is made up of the raw material of following components and weight portion：Ubiquinone1040 weight portions, the weight portion of vitamin E 50,
The weight portion of corn oil 395, the weight portion of beeswax 15.
5. a kind of ubiquinone as described in Claims 1 to 4 is any10The preparation method of soft capsule, its feature
It is that the method is comprised the following steps：
(1) preparation of capsule-core feed liquid：Beeswax, corn oil, heating fusing beeswax are taken by formula rate；By matching somebody with somebody
Square ratio takes vitamin E, ubiquinone10, mix with beeswax, corn oil, obtain capsule-core feed liquid；
(2) preparation of capsule hide glue gelatin：Purified water is heated, by gelatin, glycerine, titanium dioxide, burnt sugar coloring,
Monascus color is added in purified water, is stirred and evenly mixed, and obtains capsule hide glue gelatin；
(3) soft capsule is prepared：The capsule hide glue gelatin that capsule-core feed liquid obtained in step (1) and step (2) are prepared
Mix, by pelleting, sizing, dry, prepare ubiquinone10Soft capsule.
6. preparation method as claimed in claim 5, it is characterised in that selected gelatin in step (2),
The weight ratio of glycerine and pure water is (1~5):(0.5~2):(2~8).
7. preparation method as claimed in claim 6, it is characterised in that selected gelatin in step (2),
The weight ratio of glycerine and pure water is 3:1:4.
8. a kind of composition is preparing answering in having strengthen immunity, the health products of fatigue-relieving effect
With, it is characterised in that the raw material of the composition by as follows into being grouped into：
Ubiquinone1020-50 weight portions, vitamin E 15-60 weight portions, corn oil 200-500 weight portions,
Beeswax 5-20 weight portions.
9. application as claimed in claim 8, it is characterised in that the raw material of the composition by as follows into
It is grouped into：
Ubiquinone1030-40 weight portions, vitamin E 25-55 weight portions, corn oil 300-450 weight portions,
Beeswax 5.5-18 weight portions.
10. application of a kind of composition in preparing with the health products for dispelling facial pigmentation effect,
Characterized in that, the raw material of the composition is by as follows into being grouped into：
Ubiquinone1020-50 weight portions, vitamin E 15-60 weight portions, corn oil 200-500 weight portions,
Beeswax 5-20 weight portions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510830305.XA CN106798734A (en) | 2015-11-25 | 2015-11-25 | A kind of soft capsule containing Co-Q10 and its preparation and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510830305.XA CN106798734A (en) | 2015-11-25 | 2015-11-25 | A kind of soft capsule containing Co-Q10 and its preparation and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106798734A true CN106798734A (en) | 2017-06-06 |
Family
ID=58976429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510830305.XA Pending CN106798734A (en) | 2015-11-25 | 2015-11-25 | A kind of soft capsule containing Co-Q10 and its preparation and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106798734A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107927771A (en) * | 2017-12-29 | 2018-04-20 | 珍奥集团股份有限公司 | A kind of health food containing Co-Q10 and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083198A (en) * | 2011-10-27 | 2013-05-08 | 北京天辰空间生物医药研发有限公司 | Whitening and freckle removing functions of coenzyme Q10, and application thereof in cosmetics |
| CN103156193A (en) * | 2013-04-03 | 2013-06-19 | 上海春芝堂生物制品有限公司 | Coenzyme Q10 soft capsules and preparation method thereof |
| CN104840385A (en) * | 2015-04-11 | 2015-08-19 | 广东医学院 | A group of coenzyme Q10 skin protection creams with effects of skin moisturizing, wrinkle preventing and aging resistance |
| CN104983791A (en) * | 2015-06-18 | 2015-10-21 | 南京邦康生物技术有限公司 | Health-care product containing coenzyme Q10 and preparation method thereof |
-
2015
- 2015-11-25 CN CN201510830305.XA patent/CN106798734A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083198A (en) * | 2011-10-27 | 2013-05-08 | 北京天辰空间生物医药研发有限公司 | Whitening and freckle removing functions of coenzyme Q10, and application thereof in cosmetics |
| CN103156193A (en) * | 2013-04-03 | 2013-06-19 | 上海春芝堂生物制品有限公司 | Coenzyme Q10 soft capsules and preparation method thereof |
| CN104840385A (en) * | 2015-04-11 | 2015-08-19 | 广东医学院 | A group of coenzyme Q10 skin protection creams with effects of skin moisturizing, wrinkle preventing and aging resistance |
| CN104983791A (en) * | 2015-06-18 | 2015-10-21 | 南京邦康生物技术有限公司 | Health-care product containing coenzyme Q10 and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107927771A (en) * | 2017-12-29 | 2018-04-20 | 珍奥集团股份有限公司 | A kind of health food containing Co-Q10 and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7069490B2 (en) | Yuricoma longifolia extract and its use in enhancing and / or stimulating the immune system | |
| CN102215850B (en) | Composition containing fucoxanthin extract | |
| CN103156193A (en) | Coenzyme Q10 soft capsules and preparation method thereof | |
| CN104983791A (en) | Health-care product containing coenzyme Q10 and preparation method thereof | |
| CN104323283B (en) | Contain alimentation composition of Co-Q10 and preparation method thereof and application | |
| CN104288345A (en) | A traditional Chinese medicine composition assisting blood lipid reduction and a preparing method thereof | |
| CN102631405A (en) | Compound apigenin nanoemulsion antihypertensive drug | |
| CN104667197B (en) | A kind of composition of strengthen immunity and its preparation method and application | |
| CN103027300A (en) | VE (Vitamin E) coenzyme Q10 composition for assisting to reduce blood fat and boosting immunity and preparation method thereof | |
| CN103734696B (en) | A kind of soft capsule and preparation method thereof improving immunity, protection internal organs | |
| CN103919854B (en) | Application of butterflybush flower and extract thereof to preparation of medicament | |
| CN112156143B (en) | Compound nutrient composition with antioxidant function | |
| CN102860496B (en) | Oxidation-resisting health-care food for improving immunity and preparation method thereof | |
| WO2002011744A1 (en) | A strong antioxidant composite capsule containing grape seed extract opc and process for producing the same | |
| CN102631385A (en) | Compound anti-aging quercetin nanoemulsion health care product | |
| CN103735621B (en) | A kind of Chinese medicine composition with blood fat reducing and enhancing immunity effect | |
| CN106798734A (en) | A kind of soft capsule containing Co-Q10 and its preparation and application | |
| CN106690201A (en) | Composition with immunity enhancing function and preparation method thereof | |
| CN108653322A (en) | A kind of composition with the functional health product for preventing metastases | |
| CN103829254A (en) | Application of proanthocyanidins in preparing diet food or drug | |
| CN107183716A (en) | A kind of liver protection is dispelled wine health-care food composition and preparation method thereof | |
| CN106177227A (en) | A kind of compositions containing coenzyme Q10 strengthening body immunity | |
| CN102429180A (en) | Edible composition and preparation method as well as application thereof | |
| CN110038090A (en) | A kind of compound celery oil self-emulsifying soft capsule and preparation method thereof with antigout effect | |
| CN109758542A (en) | Compound inulol fat emulsion formulation and preparation method and application with digestion promoting function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170606 |
|
| RJ01 | Rejection of invention patent application after publication |